Saturday 17 October 2026
Export HYPR’s income statement to Excel — free account
Hyperfine, Inc.
HYPR Healthcare Medical Devices
Hyperfine, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $13.6 million, up 5.22% from fiscal 2024. In the quarter to June 2026, revenue grew 44.8%, EPS grew 25.0% and free cash flow grew 13.4%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.
0.75
0.03
−3.85%
Follow HYPR
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
8.15 | 6.88 | 5.91 | 10.82 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(18.54) | (11.71) | (15.39) | (20.53) | |
P/B ratio |
3.67 | 3.07 | 1.95 | 4.26 | |
Price to Tangible BV |
3.67 | 3.07 | 1.95 | 4.26 | |
EV/Sales |
6.24 | 5.05 | 3.25 | 8.74 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(3.81) | (2.79) | (1.58) | (2.98) | |
EV/FCF |
(3.75) | (2.70) | (1.51) | (2.87) | |
Quick Ratio |
5.25 | 4.64 | 3.63 | 2.79 | |
Current Ratio |
6.15 | 5.52 | 4.34 | 3.63 | |
Net Debt/EBITDA |
3.90 | 3.41 | 4.88 | 2.55 | |
Debt/Assets |
21.01% | 21.75% | 0.00% | 0.00% | |
Debt/Equity |
0.36 | 0.38 | 0.00 | 0.00 | |
Asset Turnover |
0.31 | 0.27 | 0.24 | 0.19 | |
Operating CF/Net income |
0.78 | 1.04 | 0.88 | 0.51 | |
Capex/Depreciation |
(0.08) | (0.83) | (0.22) | (0.44) | |
Interest Coverage |
(15.89) | (103.11) | — | — | |
Research and Development Expense of Revenue |
99.00% | 98.51% | 72.27% | 117.78% | |
Selling, General and Administrative Expense of Revenue |
168.65% | 171.46% | 123.50% | 195.52% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
23.13% | 16.58% | 13.07% | 17.95% | |
Graham Net Nets |
0.24 | 0.28 | 0.46 | 0.19 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(28.15%) | (37.96%) | (44.90%) | (35.86%) | |
Free Cash Flow Yield |
(20.43%) | (27.17%) | (36.34%) | (28.12%) | |
Revenue per Share |
0.04 | 0.04 | 0.06 | 0.04 | |
Operating CF per Share |
(0.07) | (0.09) | (0.06) | (0.07) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.07) | (0.09) | (0.06) | (0.07) | |
Cash per Share |
0.45 | 0.42 | 0.44 | 0.28 | |
Shareholders Equity per Share |
0.37 | 0.35 | 0.50 | 0.34 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.37 | 0.35 | 0.50 | 0.34 | |
Free Cash Flow |
(7.30) | (9.25) | (5.27) | (5.71) | |
Working Capital |
49.61 | 45.88 | 39.18 | 26.74 | |
Capital Expenditures |
(0.03) | (0.24) | (0.06) | (0.13) | |
Net Current Asset Value |
33.00 | 30.06 | 36.65 | 22.26 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.06 | 0.01 | 0.04 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
6.37 | 6.53 | 7.41 | 7.69 | |
Average Payables |
2.70 | 3.43 | 2.83 | 2.56 | |
Average Inventory |
5.84 | 5.48 | 6.46 | 6.44 | |
Average Assets |
54.12 | 56.86 | 57.08 | 55.45 | |
Average Common Equity |
35.94 | 38.74 | 45.02 | 42.60 |
Columns are period end dates